Clinical outcomes and adverse events will be recorded 12 hours after the end PCI or at the time of transfer to another hospital, whichever comes first. The half-life of enoxaparin is 1-2 hours when given intravenously, and therefore, adverse events are unlikely to arise following the proposed follow-up period.